Literature DB >> 24252815

Venous sac embolization of pulmonary arteriovenous malformation: safety and effectiveness at mid-term follow-up.

Kenji Kajiwara1, Masaki Urashima2, Takuji Yamagami3, Hideaki Kakizawa3, Noriaki Matsuura2, Akiko Matsuura2, Tae Ohnari2, Masaki Ishikawa3, Kazuo Awai3.   

Abstract

BACKGROUND: The standard technique for the transcatheter treatment of pulmonary arteriovenous malformations (PAVMs) involves deploying coils into the feeding arteries. We investigated whether venous sac embolization would also be a safe and useful treatment method.
PURPOSE: To evaluate the safety and outcomes of venous sac embolization for PAVMs.
MATERIAL AND METHODS: This study included 15 consecutive patients (1 man, 14 women; mean age, 54 years; range, 22-76 years) with 50 PAVMs who underwent 26 procedures; four had a history of earlier cerebral infarction or exertional dyspnea. We first placed 0.018-inch interlocking detachable and/or 0.018-inch or 0.010-inch Guglielmi detachable coils to prevent systemic migration from the venous sac. We then packed the sac as tightly as possible and embolized the orifice at the proximal feeding artery. We used angiographic, clinical, and computed tomography (CT) studies to evaluate the treatment outcomes and safety of these procedures. The mean follow-up was 16 months (range, 3-63 months) in 12 patients with 43 PAVMs; three patients (7 PAVMs) were lost to follow-up.
RESULTS: Immediate post-embolization angiography confirmed complete primary occlusion in 47 of 50 lesions (94%). Minor complications arose in two of 26 procedures (7.7%); they were abnormal electrocardiograms without symptoms during and pleurisy immediately after the procedure. During follow-up, 40 PAVMs were free of CT evidence of reperfusion. The mean partial arterial oxygen pressure increased from 75.3% ± 13.6 before embolization to 85.4% ± 16.3 after embolization (P < 0.01, t-test). Of the 12 patients who were available for follow-up, none experienced new-onset paradoxical embolization; pre-treatment exertional dyspnea was alleviated in one patient. There were no major complications.
CONCLUSION: Venous sac embolization for PAVMs might be safe and more effective with no reperfusion than the standard pulmonary arterial embolization. © The Foundation Acta Radiologica 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  AVM; Vascular; adults; embolization; interventional; lung

Mesh:

Year:  2013        PMID: 24252815     DOI: 10.1177/0284185113512123

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  5 in total

Review 1.  Angioarchitecture of Hereditary Arteriovenous Malformations.

Authors:  Patricia E Burrows
Journal:  Semin Intervent Radiol       Date:  2017-09-11       Impact factor: 1.513

Review 2.  Pulmonary arteriovenous malformations: what the interventional radiologist needs to know.

Authors:  Andrea Contegiacomo; Annemilia Del Ciello; Rossella Rella; Nico Attempati; Davide Coppolino; Anna Rita Larici; Carmine Di Stasi; Giuseppe Marano; Riccardo Manfredi
Journal:  Radiol Med       Date:  2019-06-17       Impact factor: 3.469

3.  Location of embolization affects patency after coil embolization for pulmonary arteriovenous malformations: importance of time-resolved magnetic resonance angiography for diagnosis of patency.

Authors:  Masashi Shimohira; Hiro Kiyosue; Keigo Osuga; Hideo Gobara; Hiroshi Kondo; Tetsuro Nakazawa; Yusuke Matsui; Kohei Hamamoto; Tomoya Ishiguro; Miyuki Maruno; Koji Sugimoto; Masamichi Koganemaru; Akira Kitagawa; Koichiro Yamakado
Journal:  Eur Radiol       Date:  2021-01-15       Impact factor: 5.315

4.  Where is the Origin of the Last Normal Branch from Feeding Artery of Pulmonary Arteriovenous Malformations?

Authors:  Miyuki Maruno; Hiro Kiyosue; Norio Hongo; Shunro Matsumoto; Hiromu Mori
Journal:  Cardiovasc Intervent Radiol       Date:  2018-08-22       Impact factor: 2.740

5.  Usefulness of Hydrogel-Coated Coils in Embolization of Pulmonary Arteriovenous Malformations.

Authors:  Masashi Shimohira; Tatsuya Kawai; Takuya Hashizume; Masahiro Muto; Masanori Kitase; Yuta Shibamoto
Journal:  Cardiovasc Intervent Radiol       Date:  2018-01-17       Impact factor: 2.740

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.